AbCellera Biologics Inc (OQ:ABCL)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2215 Yukon Street
VANCOUVER BC V5Y 0A1
Tel: N/A
Website: https://www.abcellera.com
IR: See website
<
Key People
Carl L.G. Hansen
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Veronique Lecault
Co-Founder, Chief Operating Officer, Director
Andrew Booth
Chief Financial Officer
Tryn T. Stimart
Chief Compliance Officer, Corporate Secretary, Chief Legal Officer
Neil Aubuchon
Chief Commercial Officer
 
Business Overview
AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.
Financial Overview
For the fiscal year ended 31 December 2023, AbCellera Biologics Inc revenues decreased 92% to $38M. Net loss totaled $146.4M vs. income of $158.5M. Revenues reflect Royalty revenue decrease from $443M to $0K, Research fees decrease of 13% to $35.6M. Net loss reflects Research and development - Balancing val increase of 72% to $143.9M (expense), Stock-based Compensation in R&D increase of 31% to $31.8M (expense).
Employees: 586 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $565.72M as of Dec 31, 2023
Annual revenue (TTM): $38.03M as of Dec 31, 2023
EBITDA (TTM): -$209.51M as of Dec 31, 2023
Net annual income (TTM): -$146.40M as of Dec 31, 2023
Free cash flow (TTM): -$121.38M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 292,782,152 as of Feb 15, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.